Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
Cancer Res. 2015 Jan 1;75(1):159-70. doi: 10.1158/0008-5472.CAN-14-1670. Epub 2014 Nov 4.
Cancer Res. 2015.
PMID: 25371409
RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.
Hu S, Dai H, Zhang T, Fu W, Berezov SD, Chen C, Jorissen D, Takeda H, Bethune AN.
Hu S, et al. Among authors: berezov sd.
Cancer Lett. 2015 Feb 1;357(1):374-383. doi: 10.1016/j.canlet.2014.11.053. Epub 2014 Nov 27.
Cancer Lett. 2015.
Retraction in:
Cancer Lett. 2017 Aug 10;401:81. doi: 10.1016/j.canlet.2017.05.014
PMID: 25434797
Retracted.
Item in Clipboard
Correction: Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk.
Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W.
Hu S, et al. Among authors: berezov sd.
Cancer Res. 2019 Jul 1;79(13):3525. doi: 10.1158/0008-5472.CAN-19-1515.
Cancer Res. 2019.
PMID: 31262834
No abstract available.
Item in Clipboard
Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 (2015) 374-383].
Hu S, Dai H, Zhang T, Fu W, Berezov SD, Chen C, Jorissen D, Takeda H, Bethune AN.
Hu S, et al. Among authors: berezov sd.
Cancer Lett. 2017 Aug 10;401:81. doi: 10.1016/j.canlet.2017.05.014.
Cancer Lett. 2017.
PMID: 28610664
No abstract available.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.